Seeking Alpha

GlaxoSmithKline's (GSK) once-a-week Albiglutide's diabetes injection reduced glycated...

GlaxoSmithKline's (GSK) once-a-week Albiglutide's diabetes injection reduced glycated haemoglobin, an indicator of blood-sugar levels, more than a placebo and some other treatments in a series of Phase III trials, although it wasn't as good as the generic pioglitazone in one group of patients. Analysts have forecast modest sales for Albiglutide, as they believe it will have difficulty in distinguishing itself from treatments from Novo Nordisk, Bristol-Myers Squibb and AstraZeneca. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector